Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Completed

Conditions studied: Magnetic Resonance Imaging Contrast Agents

In brief

Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enhancement characteristics in the kidneys of the three GBCAs (Dotarem, Gadovist, Magnevist)

Key facts

Study ID

NCT03910114

Run by

Vanderbilt University Medical Center

People needed

500

Starts

1990-07-01

Expected to finish

2019-04-01

Last updated by the study team

2019-04-10

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pediatric population which obtained MRI/fMRU study

You may not qualify if…

• Bilateral abnormal kidneys

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Vanderbilt Childeen's Hospital — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.